Anagrelide for essential thrombocythemia

Article Abstract:

The FDA has approved anagrelide hydrochloride for treatment of essential thrombocythemia. This is a disorder which causes too many platelets in the blood, a situation which can lead to blood clots and spontaneous bleeding. The drug, marketed by Roberts as Agrylin, is taken orally and has fewer side effects than existing treatments for this disorder. Patients do not seem to develop resistance to the drug which must be taken indefinitely. Side effects include headache and diarrhea. There are reports of heart failure and heart attack, although cardiovascular effects are generally mild.

Evaluation, Product/Service Evaluation, Product introduction, Drug therapy, Blood platelet disorders, Platelet function disorders, Roberts Pharmaceutical Corp., RPCX, Agrylin (Medication)

---

Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis

Article Abstract:

Many developing countries face many problems acquiring adequate and affordable supplies of traditional vaccines or their alternatives. These alternative products include monoclonal antibodies or purified antibodies from the blood of immune humans or horses. Obstacles to effective immunization in developing countries include prohibitive production costs, inconsistent supply, wars, poor quality control, and objections from animal rights activists. Unpurified versions of vaccinations produced by many developing countries, if they are produced at all, often result in adverse reactions.

Usage, Vaccines, Antivenins, Immune serums

---

Similar abstracts:

• Abstracts: Essential fatty acids and inflammation. Novoseven for non-hemophilia hemostasis
• Abstracts: Beneficial effects of isovolemic hemodilution using a perfluorocarbon emulsion in a stroke model. Alteplase for thrombolysis in acute ischemic stroke
• Abstracts: Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites: proposal of a diagnostic sequence
• Abstracts: Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. part 2
• Abstracts: Haemophilus b disease after vaccination with Haemophilus b polysaccharide or conjugate vaccine. part 2 Edward Jenner (1749-1823): the history and effects of smallpox, inoculation, and vaccination

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.